2026-04-14T08:31:11Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/103902025-10-24T10:20:54Zcom_2072_378070com_2072_378040col_2072_378092

PRIMO Monte Carlo software as a tool for commissioning of an external beam radiotherapy treatment planning system CALVO ORTEGA, JUAN FRANCISCO Hermida López, Marcelino Institut Català de la Salut [Calvo-Ortega JF] Oncología Radioterápica, Hospital Quirónsalud Barcelona, Barcelona, Spain. Oncología Radioterápica, Hospital Quirónsalud Málaga, Malaga, Spain. [Hermida-López M] Servei de Física i Protecció Radiològica, Vall d’Hebron Hospital Universitari, Barcelona, Spain Vall d'Hebron Barcelona Hospital Campus Radioteràpia Programari Radiació - Dosimetria ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Therapy, Computer-Assisted::Radiotherapy Planning, Computer-Assisted TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::tratamiento asistido por ordenador::planificación radioterápica asistida por ordenador Monte Carlo; Commissioning Monte Carlo; Puesta en marcha Monte Carlo; Posada en marxa Background: The purpose was to validate the PRIMO Monte Carlo software to be used during the commissioning of a TPS. Materials and methods: The Acuros XB v. 16.1 algorithm of the Eclipse was configured for 6 MV and 6 MV flattening-filter-free (FFF) photon beams, from a TrueBeam linac equipped with a high-definition 120-leaf multileaf collimator (MLC). PRIMO v. 0.3.64.1814 software was used with the phase space files provided by Varian and benchmarked against the reference dosimetry dataset published by the Imaging and Radiation Oncology Core–Houston (IROC-H). Thirty Eclipse clinical intensity-modulated radiation therapy (IMRT)/volumetric modulated arc therapy (VMAT) plans were verified in three ways: 1) using the PTW Octavius 4D (O4D) system; 2) the Varian Portal Dosimetry system and 3) the PRIMO software. Clinical validation of PRIMO was completed by comparing the simulated dose distributions on the O4D phantom against dose measurements for these 30 clinical plans. Agreement evaluations were performed using a 3% global/2 mm gamma index analysis. Results: PRIMO simulations agreed with the benchmark IROC-H data within 2.0% for both energies. Gamma passing rates (GPRs) from the 30 clinical plan verifications were (6 MV/6MV FFF): 99.4% ± 0.5%/99.9% ± 0.1%, 99.8% ± 0.4% /98.9% ± 1.4%, 99.7% ± 0.4%/99.7% ± 0.4%, for the 1), 2) and 3) verification methods, respectively. Agreement between PRIMO simulations on the O4D phantom and 3D dose measurements resulted in GPRs of 97.9% ± 2.4%/ 99.7% ± 0.4%. Conclusion: The PRIMO software is a valuable tool for dosimetric verification of clinical plans during the commissioning of the primary TPS. 2023-10-02T10:33:29Z 2023-10-02T10:33:29Z 2023-07-24 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Calvo-Ortega JF, Hermida-López M. PRIMO Monte Carlo software as a tool for commissioning of an external beam radiotherapy treatment planning system. Rep Pract Oncol Radiother. 2023 Jul 24;28(4):529–40. 2604-7306 https://hdl.handle.net/11351/10390 10.5603/RPOR.a2023.0060 http://hdl.handle.net/11351/10390 eng Reports of Practical Oncology and Radiotherapy;28(4) http://dx.doi.org/10.5603/RPOR.a2023.0060 Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ info:eu-repo/semantics/openAccess application/pdf Via Medica Scientia